Affiliate disclosure: As an Amazon Associate, this site earns from qualifying purchases linked in this article.
Ready to buy? Check current prices on Amazon and compare deals before you decide.
Experiencing discomfort or pain during sexual activity is a common concern for women navigating menopause. This can significantly impact intimacy, quality of life, and overall well-being. Understanding the underlying causes is the first step toward finding effective strategies.
The primary reason for painful sex during menopause is often related to changes in the genitourinary system, collectively known as Genitourinary Syndrome of Menopause (GSM). This article will explore various evidence-based solutions, ranging from simple over-the-counter options to prescription therapies, to help manage this experience.
Understanding Genitourinary Syndrome of Menopause (GSM)
Genitourinary Syndrome of Menopause (GSM) is a collection of symptoms and physical signs that occur due to reduced estrogen levels affecting the vulvovaginal and lower urinary tract tissues [1]. These changes can lead to symptoms such as vaginal dryness, irritation, itching, and painful intercourse (dyspareunia)[1][2]. The tissues of the vagina, vulva, and urethra become thinner, less elastic, and less lubricated, which can make sexual activity uncomfortable or painful [3].
It’s important to recognize that GSM is a chronic and progressive condition, meaning symptoms can worsen over time if left unaddressed [1]. While not all women experience all symptoms of GSM, painful sex is a frequently reported concern that warrants attention and appropriate management [2].
Initial Steps: Lubricants and Vaginal Moisturizers
For many women, the first line of approach involves over-the-counter products like lubricants and vaginal moisturizers. These products can offer significant relief by addressing dryness and reducing friction during sexual activity [4].
Vaginal lubricants are typically applied just before or during sexual activity to reduce friction and improve comfort [4]. They come in various formulations, including water-based, silicone-based, and oil-based. Water-based lubricants are generally considered safe with condoms, while silicone-based options tend to last longer. Vaginal moisturizers, on the other hand, are designed for regular application (e.g., every few days) and work by adhering to the vaginal wall, providing sustained hydration and improving tissue moisture over time [4]. Some moisturizers contain hyaluronic acid, which has been shown to improve symptoms of vaginal atrophy in postmenopausal women [5]. Both lubricants and moisturizers can be effective in reducing painful sex associated with GSM [6].
Topical Hormonal Therapies
When over-the-counter options are not sufficient, local hormonal therapies can be highly effective. These therapies work by delivering estrogen directly to the vaginal tissues, helping to restore their health and function [7].
Low-dose vaginal estrogen is available in several forms, including creams, rings, and tablets [7]. These products are inserted into the vagina, where the estrogen is absorbed by the local tissues. This local application helps to thicken the vaginal walls, increase elasticity, and improve natural lubrication, thereby reducing pain during intercourse[7][2]. Vaginal estrogen has been found to be effective for genitourinary syndrome of menopause [6]. For women who have experienced breast cancer, low-dose vaginal estrogen may be considered, but careful discussion with a healthcare provider is essential to weigh individual risks and benefits [8].
Non-Estrogen Prescription Options
For women who cannot or prefer not to use estrogen, there are non-estrogen prescription options available. These therapies offer alternative mechanisms to address the symptoms of painful sex related to menopause.
Ospemifene is an oral medication that acts as a selective estrogen receptor modulator (SERM) [9]. It works by mimicking estrogen’s effects on the vaginal tissue, leading to improvements in vaginal dryness and painful intercourse[9][2]. Ospemifene has been shown to be safe and effective for the management of dyspareunia associated with vulvar and vaginal atrophy due to menopause [9]. Another option is intravaginal dehydroepiandrosterone (DHEA), which is converted into estrogens and androgens within the vaginal cells, helping to restore tissue health and reduce symptoms of GSM, including painful sex[10][2].
Other Considerations and Emerging Therapies
Beyond the primary medical interventions, other factors can contribute to or alleviate painful sex during menopause. Pelvic floor physical therapy, for instance, can be beneficial for women experiencing muscle tension or spasms that contribute to discomfort [2]. Techniques to relax and strengthen pelvic floor muscles can sometimes improve comfort during intercourse.
Emerging therapies are also being explored, though more research may be needed to establish their widespread efficacy and safety. These include technologies like laser therapy and radiofrequency treatments, which aim to rejuvenate vaginal tissue [10]. While promising, it’s important to discuss these options thoroughly with a healthcare provider to understand their current evidence base and suitability for individual circumstances [10].
References
- The genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2021
- Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. Menopause (New York, N.Y.), 2023
- Menopausal Symptoms and Their Management. Endocrinology and metabolism clinics of North America, 2015
- Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric : the journal of the International Menopause Society, 2021
- Hyaluronic Acid in Postmenopause Vaginal Atrophy: A Systematic Review. The journal of sexual medicine, 2021
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. Annals of internal medicine, 2024
- Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics and gynecology, 2014
- Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update. Pharmaceuticals (Basel, Switzerland), 2023
- Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clinical interventions in aging, 2014
- New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. Medicina (Kaunas, Lithuania), 2022
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
